Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success
Sarepta Therapeutics(US:SRPT) MarketWatch·2025-11-04 07:26Sarepta's stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints. ...